R-CHOP is the standard first-line treatment for Diffuse Large B-Cell Lymphoma (DLBCL), a fast-growing type of non-Hodgkin lymphoma. It combines five drugs, each targeting cancer cells in different ways.
Here's what each letter stands for:
- R — Rituximab, an immunotherapy drug that helps the immune system find and attack Show Full Answer
R-CHOP is the standard first-line treatment for Diffuse Large B-Cell Lymphoma (DLBCL), a fast-growing type of non-Hodgkin lymphoma. It combines five drugs, each targeting cancer cells in different ways.
Here's what each letter stands for:
- R — Rituximab, an immunotherapy drug that helps the immune system find and attack cancer cells
- C — Cyclophosphamide, damages cancer cell DNA
- H — Doxorubicin (hydroxydaunorubicin), kills cancer cells
- O — Vincristine (formerly Oncovin), interferes with cancer cell growth
- P — Prednisone, a steroid that reduces inflammation and helps kill cancer cells R-CHOP is quite effective for many people. Around 60–70% of people with DLBCL are cured with R-CHOP. However, it doesn't work for everyone — about 30–40% of people may find their cancer is resistant or comes back after treatment.
Treatment is typically given in 6 cycles, once every 21 days, though early-stage cases may need fewer cycles. Radiation therapy is sometimes added depending on tumor size and scan results.
It's worth noting that some people may receive a variation of R-CHOP based on their specific situation or how well they tolerate the treatment. Always discuss with your doctor which approach is best for your case.
May 1
Join
Your Privacy Choices
